Doxorubicin hydrochloride

Cas No.:	25316-40-9
Chemical Name:	Doxorubicin Hydrochloride
Synonyms:	doxorubicin hydrochloride;Doxorubicin, HCl;(8s-cis)-10-((3-amino-2,3,6-trideoxy-alpha-l-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxynaphthacene-5,12-dione hydrochloride;DOX;ADRIAMYCIN, HYDROCHLORIDE;Doxorubicin (Adriamycin);Doxorubicin (hydrochloride);Doxorubicin hydrochloride (Adriamycin®, Adriamycin PFS®, Adriamycin RDF®, Rubex®,Adriacin®, Adriblastin®,Adriblastina®,Caelyx®, Doxil®,Farmiblastina®,Lipodox®, Myocet®);Doxorubicin;14-hydroxydaunomycin hydrochloride;ADR;ADRIACIN;Adriamycin;Ardriamycin;Caely;CAELYX;DOX HCl;Dox hydrochloride;DOX,Hydroxydaunorubicin hydrochloride;Doxorubicin (Adriamycin) HCl;FI 106;fi6804;Hydroxydaunorubicin hydrochloride;Lipodox;(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxynaphthacene-5,12-dione hydrochloride;Doxorubicin HCl;Adriblastina;Rubex;ADRIAMYCIN HYDROCHLORIDE;Adriamycin RDF;Adriamycin PFS;Adriblastin;MLS001401460;82F2G7BL4E;Resmycin;Hydroxydaunorubicin;SMR000058570;CPD000058570;DSSTox_RID_78854;DSSTox_CID_10636;DSSTox_RID_80678;DSSTox_GSID_30636;DSSTox_GSID_45111;CAS-NOCAS_
SMILES:	Cl[H].O([C@@]1([H])C([H])([H])[C@@]([H])([C@@]([H])([C@]([H])(C([H])([H])[H])O1)O[H])N([H])[H])[C@]1([H])C2C(=C3C(C4C(=C([H])C([H])=C([H])C=4C(C3=C(C=2C([H])([H])[C@@](C(C([H])([H])O[H])=O)(C1([H])[H])O[H])O[H])=O)OC([H])([H])[H])=O)O[H]
Formula:	C27H30ClNO11
M.Wt:	579.9802
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Description:	Doxorubicin hydrochloride is a cytotoxic anthracycline antibiotic for the treatment of multiple cancers. The possible mechanisms by which doxorubicin acts in the cancer cell are intercalation into DNA and disruption of topoisomerase-II-mediated DNA repair.
In Vivo:	Mice bearing PC3 xenografts are injected with 2, 4 or 8 mg/kg Doxorubicin and tumor volume is measured over time. A dose of 2 mg/kg does not affect tumor growth while higher dosages delay tumor growth initially (p<0.05 at days 18 and 22), 4 mg/kg or 8 mg/kg Doxorubicin significantly reduces levels of c-FLIP in PC3 xenografts[3]. A single intraperitoneal injection 10 mg/kg (Doxorubicin 1) is administered in rats, 10 daily intraperitoneal injections of 1 mg/kg (Doxorubicin 2), or in 5 weekly intraperitoneal injections of 2 mg/kg (Doxorubicin 3). An 80% mortality rate is observed at day 28 in Doxorubicin 1, whereas Doxorubicin 2 and Doxorubicin 3 reached 80% mortality at days 107 and 98, respectively. Fractional shortening decreased by 30% at week 2 in Doxorubicin DOX1, 55% at week 13 in Doxorubicin 2, and 42% at week 13 in Doxorubicin 3[4].
In Vitro:	Combination of Doxorubicin and Simvastatin in the highest tested concentrations (2 μM and 10 μM, respectively) kills 97% of the Hela cells[2].